Zimmer Biomet Holdings announced it plans to repurchase up to $1 billion of its common stock in fiscal year 2026, increasing its previous target by $250 million. The buybacks will be executed under the existing $1.5 billion authorization approved in February 2026. This move reflects the company's confidence in its capital position and aims to enhance shareholder value. The timing and amount of repurchases will depend on market conditions and other financial considerations.
Zimmer Biomet has appointed Chintan Desai as president of its Asia Pacific region, effective immediately. Desai brings nearly 30 years of leadership experience in the medical technology sector, including senior roles at Alcon and GE Healthcare. He re...
Zimmer Biomet Holdings announced its second quarter 2026 earnings conference call will be held on August 5 at 8:30 a.m. ET, with a news release detailing results available earlier that day. The call will be webcast live and available for replay on th...
The AI in orthopedic surgery market is projected to grow from $0.26 billion in 2025 to $0.87 billion by 2030, at a CAGR of 27.2%. Growth is fueled by increased orthopedic surgeries, innovations in medical imaging, adoption of minimally invasive techn...
